Brainstorm Cell Therapeutics (BCLI) Tops Q1 EPS by 15c
Tweet
Share
E-mailGet Alerts BCLI Hot Sheet
Join SI Premium – FREE
Brainstorm Cell Therapeutics (NASDAQ: BCLI) reported Q1 EPS of ($0.10), $0.15 better than the analyst estimate of ($0.25).
For earnings history and earnings-related data on Brainstorm Cell Therapeutics (BCLI) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Morgan Stanley sees little room left in steel rally, cuts Cleveland-Cliffs rating
- Assurant (AIZ) is Piper Sandler's Weekly Focus Idea
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
